MD Anderson and CureVac collaborate to develop mRNA cancer vaccines

VCU Massey, MD Anderson researchers awarded $7.3M grant to launch breast cancer clinical trial

Venkata Lokesh BattulaClinton YamA multidisciplinary team of researchers at VCU Massey Comprehensive Cancer Center and MD Anderson Cancer Center has been awarded a $7.3 million grant from the U.S. Department of Defense to fund a novel clinical trial targeting one of the most aggressive and hard-to-treat forms of breast cancer: metastatic triple-negative breast cancer.

September 12, 2025

Vol.51 No.33

Clinical Roundup

Checkpoint therapy breakthrough sparks new vaccine

Immune-checkpoint therapy, which attempts to harness a patient’s own immune system to fight cancer, has revolutionized cancer care over the past two decades.

September 12, 2025

Vol.51 No.33

Clinical Roundup

Novel tool helps identify key targets to strengthen CAR NK cell therapies, MD Anderson research shows

Natural killer cells became markedly better at killing cancer cells after scientists removed key gene targets identified through a new genome-wide CRISPR screening tool, according to new research from the University of Texas MD Anderson Cancer Center.

September 12, 2025

Vol.51 No.33

Capitol Hill

With CDC in free fall, RFK Jr. faces bipartisan rebuke at Senate hearing
Kennedy calls CDC “the most corrupt agency at HHS and maybe the government.”

A Senate hearing that the administration hoped would be a routine check-in on the president’s 2026 MAHA-driven healthcare agenda erupted into a political firestorm as senators jumped at their first opportunity to confront HHS Secretary Robert F. Kennedy Jr. over the chaos engulfing the Centers for Disease Control and Prevention.

September 05, 2025

Vol.51 No.32

By Claire Marie Porter

Cancer Policy

The departure (and return) of Vinay Prasad

At the end of July, after just a few months as director of the Center for Biologics Evaluation and Research, Vinay Prasad resigned.

September 05, 2025

Vol.51 No.32

By Claire Marie Porter

Clinical Roundup

Off-the-shelf cancer vaccine elicits strong immune response in patients with pancreatic and colorectal cancer

ELI-002 2P, an off-the-shelf cancer vaccine, can trigger powerful and lasting immune responses, and may help prevent or delay cancer recurrence in high-risk patients whose tumors are driven by KRAS mutations, according to a study published in Nature Medicine.

September 05, 2025

Vol.51 No.32

MD Anderson and CureVac collaborate to develop mRNA cancer vaccines

YOU MAY BE INTERESTED IN

VCU Massey, MD Anderson researchers awarded $7.3M grant to launch breast cancer clinical trial

Checkpoint therapy breakthrough sparks new vaccine

Novel tool helps identify key targets to strengthen CAR NK cell therapies, MD Anderson research shows

With CDC in free fall, RFK Jr. faces bipartisan rebuke at Senate hearing
Kennedy calls CDC “the most corrupt agency at HHS and maybe the government.”

The departure (and return) of Vinay Prasad

Off-the-shelf cancer vaccine elicits strong immune response in patients with pancreatic and colorectal cancer

Renew today!

Subscriber content

Never miss an issue!

Login

MD Anderson and CureVac collaborate to develop mRNA cancer vaccines

YOU MAY BE INTERESTED IN

VCU Massey, MD Anderson researchers awarded $7.3M grant to launch breast cancer clinical trial

Checkpoint therapy breakthrough sparks new vaccine

Novel tool helps identify key targets to strengthen CAR NK cell therapies, MD Anderson research shows

With CDC in free fall, RFK Jr. faces bipartisan rebuke at Senate hearingKennedy calls CDC “the most corrupt agency at HHS and maybe the government.”

The departure (and return) of Vinay Prasad

Off-the-shelf cancer vaccine elicits strong immune response in patients with pancreatic and colorectal cancer

Never miss an issue!

Login

With CDC in free fall, RFK Jr. faces bipartisan rebuke at Senate hearing
Kennedy calls CDC “the most corrupt agency at HHS and maybe the government.”